|1.||Nakano, Hitoo: 3 articles (05/2008 - 10/2005)|
|2.||Tsukimori, Kiyomi: 3 articles (05/2008 - 10/2005)|
|3.||Wake, Norio: 2 articles (05/2008 - 06/2007)|
|4.||Tsushima, Akitoshi: 2 articles (05/2008 - 10/2005)|
|5.||Fukushima, Kotaro: 2 articles (05/2008 - 10/2005)|
|6.||Hu, Jinyue: 2 articles (06/2007 - 04/2006)|
|7.||Gong, Wanghua: 2 articles (06/2007 - 04/2006)|
|8.||Chen, Keqiang: 2 articles (06/2007 - 04/2006)|
|9.||Zhou, Xiang-Dong: 2 articles (03/2007 - 04/2006)|
|10.||Bian, Xiu-Wu: 2 articles (03/2007 - 04/2006)|
|1.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/01/1990 - "Studies in our laboratory have shown that polymorphonuclear leucocytes (PMNL) from chronic myeloid leukemia (CML) patients are defective in chemotaxis towards a synthetic peptide, n-formyl-methionyl-leucyl-phenylalanine (FMLP), during the active phases of the disease and in remission. "
01/01/1989 - "The chemotactic index (C.I.) of granulocytes from chronic myeloid leukemia (CML) patients at diagnosis and in subsequent remission was measured using different concentrations of the synthetic chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP), by time lapse cinematography and compared with that of normal granulocytes. "
03/01/2006 - "PMNL from chronic myeloid leukemia (CML) patients have been reported to be defective in locomotion in response to synthetic peptide, n-formyl-methionyl-leucyl-phenylalanine (fMLP) but the mechanism leading to defective locomotion and their spatial reorganization remains unclear. "
01/01/2000 - "Chemotaxis of polymorphonuclear leukocytes (PMNL) from chronic myeloid leukemia (CML) patients followed in a gradient of a chemotactic peptide n-formyl-methionyl-leucyl-phenylalanine (fMLP) is consistently defective in all the phases of the disease. "
01/01/1995 - "Polymorphonuclear leukocytes (PMNL) from chronic myeloid leukemia (CML) patients are defective for chemotaxis in response to the synthetic chemotactic peptide n-formyl-methionyl-leucyl-phenylalanine (fMLP) as compared to normal PMNL. "
09/01/2001 - "Our result will help in assessing the relevance of N-formylated peptide-specific T cells in protection against infections within the human immune system."
01/01/2013 - "Our gene network and pathway analysis showed that the most significantly differentially expressed genes involved in the host response to HN878, compared to CDC1551, at 3 hours of infection, were components of the inflammatory response and STAT1 activation, recruitment and activation of macrophages, PMN, and fMLP (N-formyl-Methionyl-Leucyl-Phenylalanine)-stimulation. "
05/01/2006 - "We found that HCMV infection without N-formyl-methionyl-leucyl-phenylalanine (fMLP) stimulation increased the surface expression of CD11b to the same extent as fMLP stimulation of mock infected cells. "
06/01/1991 - "On the basis of its potent proinflammatory and spasmogenic effects, N-formyl-methionyl-leucyl-phenylalanine (FMLP), a bacterial oligopeptide, is a putative mediator of bronchoconstriction and airway inflammation during bacterial bronchial infection. "
01/01/2002 - "We investigated chemoattractant (N-formyl-methionyl-leucyl-phenylalanine, fMLP and casein) induced cytoskeletal rearrangements (polarization) of blood granulocytes in 77 adults with chronic and recurrent therapy-resistant infections of the upper and lower airways. "
|3.||Asthma (Bronchial Asthma)
01/01/2006 - "F-met-leu-phe increased CD11b, CD35 and CD18 and decreased CD62L expression in all groups, with a greater CD35 increase in severe asthma. "
04/01/1990 - "Eosinophils from patients with asthma demonstrated significantly (p less than 0.02) increased chemotactic responses to allergen-challenge serum, zymosan-activated serum, and N-formyl-methionyl-leucyl-phenylalanine, compared with eosinophils from references. "
05/01/1989 - "Adenosine inhibited N-formyl-methionyl-leucyl-phenylalanine-stimulated O2- anion generation in a dose-related fashion in subjects with asthma and normal subjects to a similar degree. "
05/01/1989 - "O2- anion generation in subjects with asthma was significantly higher compared with that of normal subjects after stimulation with either N-formyl-methionyl-leucyl-phenylalanine (mean, 14.8 nmol/10(6) cells for subjects with asthma versus mean, 9.6 nmol/10(6) cells for normal subjects; p less than 0.01) or phorbol myristate acetate (mean, 13.6 nmol/10(6) cells versus mean, 8.1 nmol/10(6) cells; p less than 0.05). "
11/01/1997 - "Eosinophils were isolated from human volunteers with a history of allergic rhinitis and/or mild asthma and were activated by incubation with cytochalasin B (5 micrograms/ml) and N-formyl-methionyl-leucyl-phenylalanine (FMLP, 1 microM). "
07/01/2008 - "We hypothesized that p21 is an important modifier of lung inflammation and injury, and genetic ablation of p21 will confer protection against CS and other pro-inflammatory stimuli (lipopolysacchride [LPS] and N-formyl-methionyl-leucyl-phenylalanine [fMLP])-mediated lung inflammation and injury. "
01/01/1995 - "Therefore, to better understand the role of eosinophils in lung inflammation, we compared the ability of three known chemoattractants, formylmethionylleucylphenylalanine (FMLP), leukotriene B4 (LTB4), and platelet-activating factor (PAF), to induce human eosinophils to migrate across 3.0-microns-pore naked filters and human umbilical vein endothelial cells (HUVEC) and A549 human pulmonary type II-like epithelial (A549) cells cultured in monolayers on these filters. "
11/01/2006 - "The aim of this study was to investigate the effect of abnormal intestinal oligopeptide transporter (PepT1) on rat colon inflammation by transportion of N-formyl-methionyl-leucyl-phenylalanine (fMLP). "
01/01/2010 - "To modulate IR-induced inflammation the neutrophils were stimulated with N-formyl-methionyl-leucyl phenylalanine (FMLP) and lipopolysaccharide (LPS). "
06/01/1996 - "N-formyl-methionyl-leucyl-phenylalanine (fMLP), a bacterial derivative, induces and modulates various cellular responses linked to inflammation. "
02/01/1992 - "Effects of f-Met-Leu-Phe-induced inflammation on intestinal lymph flow and lymphatic pump behavior."
03/01/2007 - "In the present study, we investigated the in vivo capacity of transmigrated monocytes and granulocytes to express CD11b at the site of interstitial inflammation in 10 patients on biocompatible high-flux hemodiafiltration or high-flux hemodialysis and 12 healthy subjects, and the in vitro response to a bacteria-related peptide (N-formyl-methionyl-leucyl-phenylalanine (fMLP)). "
|3.||Reactive Oxygen Species (Oxygen Radicals)
|6.||Interleukin-8 (Interleukin 8)
|7.||Complement System Proteins (Complement)
|1.||Renal Dialysis (Hemodialysis)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)